• Q2 net revenue grew 18% year-over-year to a record $21.7 million
• Gross profit margin increased to 81.9%
• Raised full-year 2026 net revenue guidance to $86M-$89M
• Expects to reach cash flow breakeven in Q4 2026

AVITA Medical reported strong financial results for the second quarter of 2026. The company saw a significant increase in net revenue, growing 18% year-over-year to a record $21.7 million. This growth was driven by continued execution across the company's key commercial portfolio, led by RECELL, and supported by Cohealyx and PermeaDerm. Gross profit margin also improved to 81.9%, reflecting the growth of RECELL and the expansion of the company's product portfolio. AVITA Medical raised its full-year 2026 net revenue guidance to a range of $86 million to $89 million, reflecting confidence in continued commercial execution. Additionally, the company expects to achieve cash flow breakeven in the fourth quarter of 2026.

Raised full-year 2026 net revenue guidance to $86M-$89M

Expects to reach cash flow breakeven in Q4 2026